AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00919308 — intervention group
Intervention type: OTHER
Intervention: Competency based simulation training
Description: Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
Study NCT01087970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously, for maximum of 6 cycles.
Study NCT01087970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression.
Study NCT01087970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously, for a maximum of 6 cycles
Study NCT01087970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously, for a maximum of 6 cycles
Study NCT02636907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 Autoinjector
Study NCT02636907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 Prefilled syringe
Study NCT00631033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00631033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Study NCT00631033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Diazoxide
Study NCT02799797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided long axis placement of adductor canal catheter
Description: The long axis of the ultrasound probe is placed parallel to the long axis of the adductor canal while scanning, and the catheter is placed along the long axis of the canal using an in-plane approach
Study NCT02799797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided short axis placement of adductor canal catheter
Description: The long axis of the ultrasound probe is placed vertical to the long axis of the adductor canal while scanning, and the catheter is placed along the short axis of the canal using an in-plane approach
Study NCT02799797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philip CX 50 Ultrasound Scanner
Description: The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning
Study NCT02799797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philip CX 50 Ultrasound Scanner
Description: The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning
Study NCT02799797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAJUNK Contiplex S Catheter
Study NCT02799797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAJUNK Contiplex S Catheter
Study NCT02799797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivocaine
Description: 0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.
Study NCT02799797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivocaine
Description: 0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.
Study NCT02799797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue sulfentanil given postoperatively as PICA
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg
Study NCT02799797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rescue sulfentanil given postoperatively as PICA
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg
Study NCT04104568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSupport for dementia - European-Portuguese version
Description: iSupport for dementia, European-Portuguese version consists in an online self-help training and support program developed by the World Health Organization to to provide education, skills training and support to informal caregivers of people with dementia and culturally adapted to Portugal by the Institute of Biomedical Sciences Abel Salazar and CINTESIS. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques. The program comprises 23 lessons on dementia and caregiver support distributed by 5 modules: 'Introduction to dementia'; 'Being a carer'; 'Caring for me'; 'Providing everyday care' and 'Dealing with behavior changes'. The education plan can be personalized by the caregiver and each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed.
Study NCT04104568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-book (comparator)
Description: The e-book contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
Study NCT01362725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation system
Description: An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
Study NCT01658943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01658943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT01658943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT01658943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT02396875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling and exercise protocol pre and post CRT implant
Study NCT02396875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral blood sampling
Study NCT02396875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central blood sampling pre and post CRT implant
Study NCT02396875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling
Study NCT03519828 — intervention group
Intervention type: OTHER
Intervention: No intervention has been conducted
Description: It is an observational study, and no intervention has been conducted
Study NCT04814745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal infusion
Description: morphine 150 mcg will be used by intrathecal administration
Study NCT04814745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion
Description: tramadol administration
Study NCT04814745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: bilateral transversus abdominis plane block by using ropivacaine 80 mg
Study NCT04109222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT04109222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose vaccine, 2019-2020 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT01909869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXCEL-Ⅱ
Description: A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
Study NCT01686542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI plus renal sympathetic modification
Description: CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
Study NCT01686542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI
Description: CPVI alone to reduce atrial arrhythmia recurrence.
Study NCT00583895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% ImCOOH cream
Description: Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
Study NCT01979081 — intervention group
Intervention type: OTHER
Intervention: Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal
Study NCT00101582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00101582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Study NCT00101582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chemotherapy
Description: Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 22, and 43.
Study NCT00101582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin chemotherapy
Description: Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 22, and 43.
Study NCT00101582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
Study NCT00101582 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
Study NCT02314338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
Study NCT01056796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAR™ 27
Description: Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
Study NCT01843608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Intervention
Description: The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
Study NCT00751465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task Concentration Training
Description: Task Concentration Training TCT following Bögels et al. (1997).
Study NCT00751465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CBT
Description: Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
Study NCT04744909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeTrach for tracheotomy
Description: The navigation system is a forceps-like instrument with an outer and an inner shank. The inner shank serves as a ventilation lumen and stabilizes the orotracheal tube in the midline of trachea. The outer shank acts as a three-dimensional guide for the puncturing needle to the midline of trachea
Study NCT04216043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUSF skimmed milk powder
Description: ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
Study NCT04216043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUSF milk protein concentrate and sucrose
Description: ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
Study NCT04216043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUSF soy protein and whey permeate
Description: ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
Study NCT04216043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUSF soy and sucrose
Description: ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
Study NCT02171533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Study NCT02171533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Study NCT02171533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil ER
Study NCT02319148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: itraconazole dosed at 200 mg
Study NCT02319148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diltiazem
Description: diltiazem dosed at 240 mg
Study NCT02319148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR verapamil
Description: SR verapamil dosed at 240 mg
Study NCT02319148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 20 mg single dose administration
Study NCT04138732 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Improve health behaviors of medical personel
Description: This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
Study NCT04138732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve health behaviors of medical personel
Description: This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
Study NCT02702960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: living related donor partial liver transplantation
Description: HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for >3 wks
Study NCT02702960 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy total body irradiation (TBI) on Day -1.
Study NCT02702960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant from same donor
Description: BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0
Study NCT02702960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
Study NCT02702960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: administered on Days 3 and 4 with PTCy
Study NCT02702960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
Study NCT02702960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
Study NCT02702960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
Study NCT02702960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
Study NCT02702960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
Study NCT02702960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine given from Days -6 to Day -2 before BMT
Study NCT00881270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Infantile (LACTIC ACID)
Study NCT02392364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Aflibercept Injection
Study NCT02287545 — intervention group
Intervention type: PROCEDURE
Intervention: trabeculectomy
Description: Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
Study NCT00005520 — intervention group
Intervention type: DRUG
Intervention: Hydrochlorothiazide
Study NCT00005520 — intervention group
Intervention type: DRUG
Intervention: Candesartan
Study NCT00003666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-hydroxymethylacylfulvene
Description: 11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
Study NCT00355628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2246 (fentanyl citrate)
Description: KW-2246
Study NCT03325114 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chlorthalidone
Description: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
Study NCT02295956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
Study NCT02295956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
Study NCT02295956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
Study NCT02295956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
Study NCT02295956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: Exercise instructional booklet given to all participants describing all exercises.
Study NCT02256007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper and Pencil Assessments
Description: Videogame Assessments
Study NCT02256007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paper and Pencil Assessments
Description: Videogame Assessments
Study NCT04558307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pilot a rapid SARS-CoV-2 testing strategy
Description: Rapid testing strategy at an FQHC using Mayo Clinic Laboratory (MCL) diagnostic processing with a real-time polymerase chain reaction assay for SARS-CoV-2 and a Mayo Clinic drive-through collection protocol.
Study NCT04558307 — intervention group
Intervention type: OTHER
Intervention: Community-driven messages to promote COVID-19 testing
Description: A one-time communication about the availability of COVID-19 testing at the FQHC to patients randomized to the intervention group using any available means of communication (text and/or mailed letter).
Study NCT01506947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:~\[Paricalcitol (µg) = iPTH (pg/mL) / 80\]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels.
Study NCT01506947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level \< 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.